146 related articles for article (PubMed ID: 30302533)
1. Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
Chen J; Yoon SH; Grynpas MD; Mitchell J
Calcif Tissue Int; 2019 Feb; 104(2):182-192. PubMed ID: 30302533
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
Yoon SH; Chen J; Grynpas MD; Mitchell J
Bone; 2016 Sep; 90():168-80. PubMed ID: 27373502
[TBL] [Abstract][Full Text] [Related]
3. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
Yoon SH; Grynpas M; Mitchell J
Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
[TBL] [Abstract][Full Text] [Related]
4. Effect of 25-HydroxyVitamin D Deficiency and Its Interaction with Prednisone Treatment on Musculoskeletal Health in Growing Mdx Mice.
Yoon SH; Sugamori KS; Grynpas MD; Mitchell J
Calcif Tissue Int; 2018 Sep; 103(3):311-323. PubMed ID: 29691609
[TBL] [Abstract][Full Text] [Related]
5. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
[TBL] [Abstract][Full Text] [Related]
6. Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
Yoon SH; Sugamori KS; Grynpas MD; Mitchell J
Neuromuscul Disord; 2016 Jan; 26(1):73-84. PubMed ID: 26494410
[TBL] [Abstract][Full Text] [Related]
7. Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model of Duchenne Muscular Dystrophy.
Yoon SH; Grynpas MD; Mitchell J
J Bone Miner Res; 2019 Aug; 34(8):1473-1486. PubMed ID: 31188496
[TBL] [Abstract][Full Text] [Related]
8. Impact of P2RX7 ablation on the morphological, mechanical and tissue properties of bones in a murine model of duchenne muscular dystrophy.
Mohamad NS; Sinadinos A; Górecki DC; Zioupos P; Tong J
J Biomech; 2016 Oct; 49(14):3444-3451. PubMed ID: 27663621
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the bone and growth phenotype of
Wood CL; Suchacki KJ; van 't Hof R; Cawthorn WP; Dillon S; Straub V; Wong SC; Ahmed SF; Farquharson C
Dis Model Mech; 2020 Jan; 13(2):. PubMed ID: 31754018
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
11. Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice.
Gray SK; McGee-Lawrence ME; Sanders JL; Condon KW; Tsai CJ; Donahue SW
Bone; 2012 Sep; 51(3):578-85. PubMed ID: 22584007
[TBL] [Abstract][Full Text] [Related]
12. Weekly oral prednisolone improves survival and strength in male mdx mice.
Keeling RM; Golumbek PT; Streif EM; Connolly AM
Muscle Nerve; 2007 Jan; 35(1):43-8. PubMed ID: 16969833
[TBL] [Abstract][Full Text] [Related]
13. Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia.
Wood CL; van 't Hof R; Dillon S; Straub V; Wong SC; Ahmed SF; Farquharson C
J Endocrinol; 2022 Mar; 253(2):63-74. PubMed ID: 35191394
[TBL] [Abstract][Full Text] [Related]
14. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
15. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
16. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
[TBL] [Abstract][Full Text] [Related]
17. Lipocalin 2 Influences Bone and Muscle Phenotype in the
Ponzetti M; Ucci A; Maurizi A; Giacchi L; Teti A; Rucci N
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055145
[TBL] [Abstract][Full Text] [Related]
18. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
19. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
